ISRCTN74516835已完成1 期
A two part, four way crossover, randomised, open-label study designed to evaluate the relative bioavailability of novel oral alectinib tablet formulations compared with oral reference alectinib capsule, in the fasted and fed state in healthy subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy males or non-pregnant, non-lactating healthy females of non-childbearing potential
- •2. Aged 18 to 55 years inclusive at the time of signing informed consent
- •3. Body mass index (BMI) of 18.0 to 32.0 kg/m² as measured at screening
- •4. Must be willing and able to communicate and participate in the whole study
- •5. Must provide written informed consent
- •6. Must agree to adhere to the contraception requirements
排除标准
- •1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
- •2. Subjects who are, or are immediate family members of, a study site or sponsor employee
- •3. Evidence of current SARS-CoV-2 infection
- •4. History of any drug or alcohol abuse in the past 2 years
- •5. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
- •6. A confirmed positive alcohol breath test at screening or admission
- •7. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
- •8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
- •9. Females of childbearing potential including those who are pregnant or lactating (all female subjects must have a negative highly sensitive serum pregnancy test at screening and urine at all other time points). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone [FSH] concentration =40 IU/L)
- •10. Male subjects with pregnant or lactating partners
- •11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
- •12. Clinically significant abnormal clinical chemistry, haematology or urinalysis at screening as judged by the investigator. Subjects will be excluded if they have ALT, AST or total bilirubin above the upper limit of the reference range or haemoglobin less than the lower limit of the reference range, neutrophil or lymphocyte count below the lower limit of normal or creatine kinase 1.25 × the upper limit of the reference range without an alternative explanation (e.g. physical activity)
- •13. Confirmed positive drugs of abuse test result at screening or admission
- •14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results
- •15. Evidence of renal impairment at screening, as indicated by an estimated glomerular filtration rate (eGFR) of <80 mL/min/1.73m² using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or any other evidence of renal impairment
- •16. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator or history of visual disturbances (e.g. blurred vision, vitreous floaters, visual impairment, reduced visual acuity, asthenopia, and diplopia) unless determined to be clinically not significant by agreement between the investigator and the sponsor’s medical monitor
- •17. Subjects with a history of cholecystectomy or gall stones
- •18. Subjects with known deglutition/oesophageal pathology which can affect transit of food/drink, or who have any swallowing difficulties/evidence of swallowing impairment
- •19. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- •20. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
- •21. Subjec
研究者
相似试验
已完成
不适用
An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects.chronic inflammation of the bronchial tubesshortness of breath10024970NL-OMON37181GlaxoSmithKline36
已完成
1 期
A study in healthy volunteers to assess two different formulations (recipes) of the drug product (Alectinib)CancerISRCTN40852430Chugai Pharmaceutical Co., Ltd.32
已完成
不适用
A randomized, open-label, four-way cross-over, single dose study to compare the pharmacokinetics of monomethyl fumarate and other metabolites after administration of dimethyl fumarate as a delayed- and slow-release formulation of FP187 and Tecfidera® in healthy volunteers.10029305Multiple SclerosisNL-OMON42906Forward Pharma GmbH24
招募中
1 期
A clinical trial to study the effect of SMC021 on the blood levels of ibuprofen and paracetamol and the effect of ibuprofen and paracetamol in blood levels of SMC021CTRI/2009/091/001052ovartis Healthcare Pvt Ltd56
进行中（未招募）
不适用
Study to investigate the effect of Gaviscon® Double Action, Gaviscon® Advance and Placebo Liquid Vs no treatment on the acid pocket.EUCTR2012-000678-44-GBReckitt Benckiser Healthcare (UK) Ltd